Page last updated: 2024-12-05

cordycepin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6303
CHEMBL ID305686
CHEBI ID29014
SCHEMBL ID98323
MeSH IDM0162242

Synonyms (71)

Synonym
MLS001066343
smr000058644
CHEMBL305686 ,
9-(beta-d-3'-deoxyribofuranosyl)adenine
einecs 200-791-4
9h-purine, 6-amino-9-(3-deoxy-beta-d-ribofuranosyl)-
beta-d-erythro-pentofuranoside, adenine-9 3-deoxy-
nsc 401022
ccris 3233
brn 0035194
9h-purin-6-amine, 9-(3-deoxy-beta-d-erythro-pentofuranosyl)-
PDSP2_001017
cordycepine
9-cordyceposidoadenine
nsc-63984
2'-hydroxy-3'-deoxyadenosine erythro
(2r,3r,5s)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol
adenosine, 3'-deoxy-
2'-oh-3'-da erythro
nsc-401022
3AD ,
cordycepin ,
3'-deoxyadenosine
C08431
73-03-0
cordycepin, from cordyceps militaris
PDSP1_001033
CHEBI:29014 ,
3''-deoxyadenosine
9-(beta-d-3''-deoxyribofuranosyl)adenine
bdbm50144950
(2r,3r,5s)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
A837698
4-26-00-03594 (beilstein handbook reference)
unii-gz8vf4m2j8
gz8vf4m2j8 ,
(2r,3r,5s)-2-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3-ol
HMS2234E22
S3610
AKOS015902254
AKOS015854875
9-(3-deoxy-.beta.-d-ribofuranosyl)adenine
cordycepin [who-dd]
cordycepin [inci]
cordycepin [mi]
(2r,3r,5s)-2-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
gtpl4630
3'-deoxy-adenosine
SCHEMBL98323
MLS006012047
AM85418
TCMDC-143080
9-(3-deoxy-b-d-erythro-pentofuranosyl)-9h-purin-6-amine
AC-22613
DTXSID1041007
CS-W009017
cordycepin, >=98.0% (hplc)
NCGC00092360-03
DB12156
HY-N0262
HMS3677C16
cordycepin,(s)
Q2256677
adenine cordyceposide
9-cordyceposidoadenosine
AS-11189
HMS3413C16
CCG-266973
STARBLD0009677
EN300-7373269
Z3041517973

Research Excerpts

Overview

Cordycepin is a purine nucleoside anti-metabolite and anti-biotic isolated from the fungus Cordyceps militaris. It is a natural active substance with significant anticancer activity and doxorubicin is a broad-spectrum anticancer drug.

ExcerptReferenceRelevance
"Cordycepin is a purine nucleoside anti-metabolite and anti-biotic isolated from the fungus Cordyceps militaris, which has potential anti-neoplastic activities. "( Cordycepin inhibits colon cancer proliferation by suppressing MYC expression.
Li, K; Liu, Y; Zhang, Z; Zheng, Z, 2022
)
3.61
"Cordycepin is a natural active substance with significant anticancer activity and doxorubicin is a broad-spectrum anticancer drug."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.74
"Cordycepin is an adenosine derivative and is isolated from the culture filtrate of Cordyceps militaris."( Protective Effect of Cordycepin on Impairment of Endothelial Function in Type 2 Diabetes Mellitus.
Gu, XD; Jia, FC; Li, L; Liu, Y; Liu, Z; Luo, Z; Wang, W; Xue, B; Zhang, JC, 2022
)
1.76
"Cordycepin is an essential nucleoside antibiotic with a broad spectrum of physiological functions, which is currently produced by the fermentation of Cordyceps militaris. "( Cordycepin production by a novel endophytic fungus Irpex lacteus CHG05 isolated from Cordyceps hawkesii Gray.
Deng, G; Jiang, J; Leng, G; Liu, Z; Wen, J, 2022
)
3.61
"Cordycepin is a nucleoside antibiotic with various biological activities, which has wide applications in the area of cosmetic and medicine industries. "( High-level de novo biosynthesis of cordycepin by systems metabolic engineering in Yarrowia lipolytica.
Duan, XY; Ji, XJ; Lin, WB; Liu, HH; Lu, XY; Song, LP; Song, ZQ; Tian, Y; Wang, C; Yang, H, 2022
)
2.44
"Cordycepin is an important quality control marker in Cordyceps militaris. "( Poly-pathways metabolomics for high-yielding cordycepin of Cordyceps militaris.
Han, C; Qi, D; Sun, M; Wang, X; Yu, J, 2023
)
2.61
"Cordycepin (CCS) is a novel neuroprotective compound obtained from Cordyceps militaris."( Cordycepin improved neuronal synaptic plasticity through CREB-induced NGF upregulation driven by MG-M2 polarization: a microglia-neuron symphony in AD.
Du, K; Fu, J; Jiao, L; Liu, J; Liu, M; Ma, G; Shen, J; Tong, J; Wei, M; Wu, Y; Xing, L; Yao, W; Yu, Z; Zhong, X, 2023
)
3.07
"Cordycepin is a bioactive compound extracted from Cordyceps militaris. "( Cordycepin: A review of strategies to improve the bioavailability and efficacy.
Chen, L; Chen, M; Han, C; Jiang, W; Luo, J; Miao, L, 2023
)
3.8
"Cordycepin is an active anti-cancer component extracted from"( Cordycepin Inhibits Human Gestational Choriocarcinoma Cell Growth by Disrupting Centrosome Homeostasis.
Chen, TY; Chien, HH; Huang, BM; Sheu, SY; So, EC; Tsai, SW; Wang, CY, 2020
)
2.72
"Cordycepin is an adenosine derivative isolated from "( The Role of Autophagy in Anti-Cancer and Health Promoting Effects of Cordycepin.
Chen, CH; Chen, RJ; Chen, YC; Chen, YY; Huang, BM; Lin, WC; Tung, CW; Yang, SH, 2021
)
2.3
"Cordycepin is a promising drug candidate in multiple therapeutic areas, and there is a growing interest in studies aimed at assessing the pharmacological activity of this compound in relevant animal disease models."( Development of Cordycepin Formulations for Preclinical and Clinical Studies.
Adrower, C; de Moor, CH; Fischer, PM; Gershkovich, P; Lee, JB; Qin, C, 2017
)
1.53
"Cordycepin is an endogenous nucleoside with significant anticancer biological activity. "( Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes.
Bi, YE; Lee, RJ; Li, L; Teng, L; Wang, M; Xie, J; Zhou, Y, 2017
)
2.22
"Cordycepin is an active component extracted from Traditional Chinese medical herb Cordyceps militaris. "( Cordycepin induces apoptotic cell death and inhibits cell migration in renal cell carcinoma via regulation of microRNA-21 and PTEN phosphatase.
Wen, J; Yang, C; Yuan, W; Zhao, L, 2017
)
3.34
"Cordycepin is a derivative of the nucleoside adenosine; also, it is speculated to exert neuroprotective effects against Aβ-induced oxidative toxicity in hippocampal neurons."( Neuroprotective effects of cordycepin inhibit Aβ-induced apoptosis in hippocampal neurons.
Gong, Y; Huang, LP; Li, Y; Liu, C; Liu, XP; Meng, W; Song, H; Wang, S; Wei, S; Yao, LH, 2018
)
1.5
"Cordycepin is a small molecule from medicinal mushroom Cordyceps, which has been reported for anticancer properties."( Cordycepin Downregulates Cdk-2 to Interfere with Cell Cycle and Increases Apoptosis by Generating ROS in Cervical Cancer Cells: in vitro and in silico Study.
Halim, MA; Khan, MA; Khorram, MS; Kiefer, R; Saif, K; Shawon, J; Tania, M, 2019
)
3.4
"Cordycepin is a nucleotide analogue from Cordyceps mushrooms, which occupies a notable place in traditional medicine."( Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects.
Khan, MA; Tania, M, 2020
)
3.44
"Cordycepin is a 3'-deoxyadenosine drug with significant anti-cancer effects."( Cordycepin suppresses cell proliferation and migration by targeting CLEC2 in human gastric cancer cells via Akt signaling pathway.
An, RB; Chen, LY; Li, ZH; Lin, ZH; Liu, TS; Lv, Y; Piao, YS; Ren, XS; Wang, Y; Yan, WD, 2019
)
2.68
"Cordycepin is an efficient component of Cordyceps spp, a traditional Chinese medicine widely used for healthcare in China, and has been recently acted as a strong anticancer agent for clinic. "( Cordycepin kills Mycobacterium tuberculosis through hijacking the bacterial adenosine kinase.
He, ZG; Huang, F; Li, W; Qin, H; Xu, H, 2019
)
3.4
"Cordycepin is an active small molecular weight compound and is implicated in modulating multiple physiological functions including immune activation, anti-aging and anti-tumor effects."( Cordycepin suppresses integrin/FAK signaling and epithelial-mesenchymal transition in hepatocellular carcinoma.
Ko, BS; Liang, SM; Liou, JY; Liu, CC; Liu, TA; Lu, YJ; Shen, TL; Tzean, SS; Yao, WL, 2014
)
2.57
"Cordycepin is a type of adenosine analog extracted from Cordyceps militaris."( Suppression of T-cell activation in vitro and in vivo by cordycepin from Cordyceps militaris.
Guan, S; Huang, G; Lu, J; Song, B; Xiong, Y; Xu, L; Zhang, S, 2013
)
1.36
"Cordycepin is a bioactive component of the fungus Cordyceps militaris. "( Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the γ1 subunit.
Guo, P; Guo, Y; He, H; Luan, H; Su, Y; Sun, G; Sun, X; Wang, X; Wu, C; Zhang, X; Zhu, H; Zhu, P, 2014
)
3.29
"Cordycepin is a derivative of the nucleoside adenosine, and is believed to exert neuroprotective effects against glutamate-induced oxidative toxicity in HT22 neuronal cells."( The neuroprotective effects of cordycepin inhibit glutamate-induced oxidative and ER stress-associated apoptosis in hippocampal HT22 cells.
Jin, ML; Kim, YH; Lee, SJ; Oh, JI; Park, G; Park, SY, 2014
)
1.41
"Cordycepin (Cor), which is a naturally occurring nucleoside derivative isolated from Cordyceps militaris, has been shown to exert excellent antiinflammatory activity in a murine model of acute lung injury. "( Cordycepin alleviates airway hyperreactivity in a murine model of asthma by attenuating the inflammatory process.
Deng, Y; He, Y; Li, T; Li, Y; Lin, R; Wang, W; Wei, J; Yang, X; Zhang, J, 2015
)
3.3
"Cordycepin is a susbtance with anti-inflammatory and anti-oxidative effects."( Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats.
He, Y; Liu, Y; Si, Z; Wang, A; Wang, D; Wang, K; Xu, S; Yuan, J; Zhang, S, 2016
)
2.6
"Cordycepin is a potent inhibitor of IL-1beta-induced chemokine production and MMP expression and strongly blocks the p38/JNK/AP-1 signalling pathway in RASFs."( Cordycepin inhibits IL-1beta-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts.
Han, MK; Hur, H; Kim, JS; Kwon, KB; Lee, SJ; Lee, YR; Noh, EM; Park, BH; Shim, IK; Song, EK; Yoo, WH; Youn, HJ, 2009
)
3.24
"Cordycepin is a potent inhibitor of TPA-induced MMP-9 expression and blocks strongly the ability of AP-1 activation via MAPK signaling pathway in MCF-7 cells."( Cordycepin inhibits TPA-induced matrix metalloproteinase-9 expression by suppressing the MAPK/AP-1 pathway in MCF-7 human breast cancer cells.
Chung, EY; Han, JH; Jeong, YJ; Jung, JY; Jung, SH; Kim, BS; Kim, JS; Lee, SH; Lee, YR; Noh, EM; Youn, HJ, 2010
)
2.52
"Cordycepin is a bioactive constituent of Cordyceps sinensis that has been shown to regulate homeostatic function. "( Pharmacokinetics of adenosine and cordycepin, a bioactive constituent of Cordyceps sinensis in rat.
Lin, LC; Tsai, TH; Tsai, YJ, 2010
)
2.08
"Cordycepin is a poly(A) polymerase inhibitor."( Cordycepin (3'-deoxyadenosine), an inhibitor of mRNA polyadenylation, suppresses proliferation and activates apoptosis in human epithelial endometriotic cells in vitro.
Fedier, A; Fink, D; Hornung, R; Imesch, P, 2011
)
2.53
"Cordycepin is an ingredient used in traditional Chinese medicine and is prescribed for various diseases, such as cancer and chronic inflammation."( Cordycepin (3'-deoxyadenosine) inhibits human platelet aggregation in a cyclic AMP- and cyclic GMP-dependent manner.
Cho, HJ; Cho, JY; Park, HJ; Rhee, MH, 2007
)
2.5

Effects

Cordycepin has a strong hypolipidemic effects, therefore, we examined its effect on lipid metabolism in CCA. It has a significant dose-dependent inhibitory effect on cell proliferation.

Cordycepin has shown the therapeutic potential for cancer by modulating multiple cellular signaling pathways. It has a strong hypolipidemic effects, therefore, we examined its effect on lipid metabolism in CCA.

ExcerptReferenceRelevance
"Cordycepin has a strong hypolipidemic effects, therefore, we examined its effect on lipid metabolism in CCA."( Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma.
Chen, D; Li, Y; Liu, T; Peng, B; Ren, X; Su, Z; Wang, T; Yan, W; Yang, C; Zhou, X, 2023
)
3.07
"Cordycepin has a significant dose-dependent inhibitory effect on cell proliferation."( Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment.
Ao, CN; Cheong, CC; Fong, P; Huang, KM; Meng, LR; Tou, KI, 2019
)
1.5
"Cordycepin has been reported to have antioxidant and neuroprotective functions."( Cordycepin Ameliorates Intracerebral Hemorrhage Induced Neurological and Cognitive Impairments Through Reducing Anti-Oxidative Stress in a Mouse Model.
Hui, K; Shao, Q; Yan, Q; Zhang, H, 2022
)
2.89
"Cordycepin has been reported to improve obesity, but the mechanism is not yet clear."( Cordycepin alleviated metabolic inflammation in Western diet-fed mice by targeting intestinal barrier integrity and intestinal flora.
Chen, J; Guo, N; Li, H; Qu, K; Wang, M; Xu, R; Zhang, P; Zhu, H, 2022
)
2.89
"Cordycepin has shown the therapeutic potential for cancer by modulating multiple cellular signaling pathways."( Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish.
Bin, XN; Fan, RY; Gao, YB; He, MF; Pan, M; Qian, ST; Tang, CL; Wu, JQ; Ying, HJ; Zhang, SR, 2023
)
1.92
"Cordycepin has been reported to alleviate cognitive impairments in neurodegenerative diseases."( Cordycepin improved the cognitive function through regulating adenosine A
Han, YY; Huang, SY; Li, CH; Liu, L; Mai, ZF; Shang, YJ; Su, ZY; Zeng, ZW, 2023
)
3.07
"Cordycepin has been reported to exhibit hepatic protective and anti-inflammatory properties. "( Protective effects of cordycepin pretreatment against liver ischemia/reperfusion injury in mice.
Jia, L; Liu, Y; Sheng, M; Yu, W; Zhu, M, 2023
)
2.67
"Cordycepin has a strong hypolipidemic effects, therefore, we examined its effect on lipid metabolism in CCA."( Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma.
Chen, D; Li, Y; Liu, T; Peng, B; Ren, X; Su, Z; Wang, T; Yan, W; Yang, C; Zhou, X, 2023
)
3.07
"Cordycepin has immunoregulatory properties, making it a promising candidate for combination therapy with NK cell-based immunotherapy."( Cordycepin Enhances the Cytotoxicity of Human Natural Killer Cells against Cancerous Cells.
Chaicharoenaudomrung, N; Kunhorm, P; Noisa, P, 2023
)
3.07
"Cordycepin has recently been shown to possess anti-inflammatory effect; however, its role and the possible underlying mechanisms in ICH remain unclear."( Cordycepin confers neuroprotection in mice models of intracerebral hemorrhage via suppressing NLRP3 inflammasome activation.
Cai, Y; Cheng, Y; Shang, H; Song, Y; Wei, Y; Wu, Z; Yang, W; Zhao, W, 2017
)
2.62
"Cordycepin has a significant dose-dependent inhibitory effect on cell proliferation."( Experimental and In Silico Analysis of Cordycepin and its Derivatives as Endometrial Cancer Treatment.
Ao, CN; Cheong, CC; Fong, P; Huang, KM; Meng, LR; Tou, KI, 2019
)
1.5
"Cordycepin has been widely recognized for its therapeutic potential against many types of cancers by various mechanisms. "( Cordycepin in Anticancer Research: Molecular Mechanism of Therapeutic Effects.
Khan, MA; Tania, M, 2020
)
3.44
"Cordycepin has many intracellular targets, including nucleic acid (DNA/RNA), apoptosis and cell cycle, etc."( Cordycepin: a bioactive metabolite with therapeutic potential.
Kashyap, D; Sandhu, SS; Sharma, AK; Tuli, HS, 2013
)
2.55
"Cordycepin has been widely used in oriental countries to maintain health and improve physical performance. "( Cordycepin Decreases Compound Action Potential Conduction of Frog Sciatic Nerve In Vitro Involving Ca (2+) -Dependent Mechanisms.
Li, YP; Liu, XP; Meng, W; Sun, W; Xiong, QP; Xu, YL; Yao, LH; Yu, HM; Yuan, CH, 2015
)
3.3
"Cordycepin has protective effects against brain damages induced by TBI."( Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats.
He, Y; Liu, Y; Si, Z; Wang, A; Wang, D; Wang, K; Xu, S; Yuan, J; Zhang, S, 2016
)
2.6
"Cordycepin has important neuroprotective effects in hypoxic or ischemic insult. "( Anti-effects of cordycepin to hypoxia-induced membrane depolarization on hippocampal CA1 pyramidal neuron.
Chen, C; Huang, LP; Jiang, W; Li, YP; Liu, XP; Meng, W; Sun, W; Yao, LH; Yuan, CH; Zeng, B, 2017
)
2.24
"Cordycepin has the effect of anti-tumor, immunomodulation, anti-inflammation and so on. "( [High-yielding cordycepin in Cordyceps militaris modified by low-energy ion beam].
Chen, H; Huang, X; Li, W; Wang, T; Yuan, H; Zhao, S, 2009
)
2.15
"Cordycepin has been shown to possess many pharmacological activities including immunological stimulation, and anti-bacterial, anti-viral, and anti-tumor effects."( Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells.
Choi, YH; Hong, SH; Jeong, JW; Jeong, YK; Jin, CY; Kim, GY; Lee, JD; Park, C; Yoo, YH, 2011
)
1.39
"Cordycepin has been shown to interfere with a myriad of molecular processes from RNA elongation to kinase activity, and prevents numerous inflammatory processes in animal models. "( Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Boulares, AH; Errami, Y; Ju, J; Kim, H; Naura, AS,
)
3.02
"Cordycepin has been a traditional medicine in China and Korea for centuries. "( Suppression of α-MSH and IBMX-induced melanogenesis by cordycepin via inhibition of CREB and MITF, and activation of PI3K/Akt and ERK-dependent mechanisms.
Jin, ML; Kim, YH; Lee, SJ; Park, G; Park, SY; Son, HJ, 2012
)
2.07

Actions

Cordycepin can inhibit SW480 and SW620 cell proliferation and induce apoptosis. It is able to suppress colon cancer cell proliferation, likely mediated by the MYC/miR-26a pathway, supporting its potential for the treatment of colon cancer.

ExcerptReferenceRelevance
"Cordycepin is able to suppress colon cancer cell proliferation, likely mediated by the MYC/miR-26a pathway, supporting its potential for the treatment of colon cancer."( Cordycepin inhibits colon cancer proliferation by suppressing MYC expression.
Li, K; Liu, Y; Zhang, Z; Zheng, Z, 2022
)
3.61
"Cordycepin could inhibit the activation of theTLR-4/NF-κB/MMP-9 pathway, which further attenuated cognitive dysfunction, and disruption of the blood-brain barrier (BBB) in HH and LPS exposed rats."( Cordycepin ameliorates acute hypobaric hypoxia induced blood-brain barrier disruption, and cognitive impairment partly by suppressing the TLR4/NF-κB/MMP-9 pathway in the adult rats.
Cui, L; Deng, H; Hu, Y; Jiang, J; Li, T; Liu, P; Pan, L; Tao, X; Wang, Y; Xue, X; Zhao, B; Zhao, S, 2022
)
2.89
"Cordycepin showed lower cytotoxicity in vitro compared with cisplatin, anlotinib and etoposide, but showed comparable anti-proliferation and anti-BM effects in zebrafish SCLC xenograft model. "( Efficacy and mechanism study of cordycepin against brain metastases of small cell lung cancer based on zebrafish.
Bin, XN; Fan, RY; Gao, YB; He, MF; Pan, M; Qian, ST; Tang, CL; Wu, JQ; Ying, HJ; Zhang, SR, 2023
)
2.64
"Cordycepin may enhance NK cell function and have clinical applications, but more research is needed."( Cordycepin Enhances the Cytotoxicity of Human Natural Killer Cells against Cancerous Cells.
Chaicharoenaudomrung, N; Kunhorm, P; Noisa, P, 2023
)
3.07
"Cordycepin can inhibit human tongue cancer cell growth and can drive their apoptotic death via the mitochondrial pathway. "( Cordycepin induces apoptosis in human tongue cancer cells in vitro and has antitumor effects in vivo.
Li, S; Li, W; Sun, J; Zhang, K; Zheng, Q, 2020
)
3.44
"Cordycepin treatment to enhance osteogenesis may be considered a potential therapeutic approach to prevent the development of alcohol-induced ONFH."( The Protective Effect of Cordycepin On Alcohol-Induced Osteonecrosis of the Femoral Head.
Chen, YX; Gao, YS; Mei, J; Xu, ZL; Yin, JH; Yu, XW; Zhang, CQ; Zhu, DY, 2017
)
2.2
"Cordycepin plays an important role in modulating the function of central nervous system (CNS). "( Cordycepin suppresses excitatory synaptic transmission in rat hippocampal slices via a presynaptic mechanism.
Cai, ZL; Huang, JN; Li, CH; Li, HH; Liu, WX; Xiao, P; Yan, WW; Yao, LH, 2013
)
3.28
"Cordycepin can inhibit the proliferation of RM-1 cells with IC₅₀ of 133 µmol/L, but it has no inhibitory effect on SH-SY5Y cells."( Optimization of fermentation conditions and purification of cordycepin from Cordyceps militaris.
Jiapeng, T; Li, Z; Yiting, L, 2014
)
1.37
"Cordycepin can inhibit the proliferation and induct the apoptosis of A549 cells, the mechanism of action is achieved by inhibiting the NF-κB pathway."( [Effects of Cordycepin on Proliferation, Apoptosis and NF-κB Signaling Pathway in A549 Cells].
Feng, T; He, XM; Hu, DX; Li, QL; Zhang, C; Zhang, XF; Zhong, Q, 2015
)
2.24
"Cordycepin can inhibit SW480 and SW620 cell proliferation and induce apoptosis. "( Cordycepin induces apoptosis by enhancing JNK and p38 kinase activity and increasing the protein expression of Bcl-2 pro-apoptotic molecules.
Fang, X; He, W; Jiang, TT; Song, Y; Ye, J; Zhang, MF, 2010
)
3.25

Treatment

Cordycepin treatment could ameliorate ICH-induced neurological deficits, brain edema, anxiety, cognitive impairments, oxidative stress and antioxidant capacity. Treatment resulted in around 50% inflammatory cytokine production (e.g. inflammatory responses in the livers of IR mice)

ExcerptReferenceRelevance
"Cordycepin treatment could ameliorate ICH-induced neurological deficits, brain edema, anxiety, cognitive impairments, oxidative stress and antioxidant capacity in ICH mice."( Cordycepin Ameliorates Intracerebral Hemorrhage Induced Neurological and Cognitive Impairments Through Reducing Anti-Oxidative Stress in a Mouse Model.
Hui, K; Shao, Q; Yan, Q; Zhang, H, 2022
)
3.61
"Cordycepin treatment resulted in around 50% inflammatory cytokine production (e.g."( Cordycepin exhibits anti-bacterial and anti-inflammatory effects against gastritis in Helicobacter pylori-infected mice.
Feng, Y; Gao, F; Hui, W; Kong, W; Liu, H; Liu, W; Lu, J; Miranbieke, B; Wang, M, 2022
)
2.89
"Cordycepin pretreatment also reduced histopathological changes, attenuated hepatocyte apoptosis, inflammatory responses in the livers of IR mice."( Protective effects of cordycepin pretreatment against liver ischemia/reperfusion injury in mice.
Jia, L; Liu, Y; Sheng, M; Yu, W; Zhu, M, 2023
)
1.95
"Cordycepin treatment significantly reduced Cd-induced embryotoxicity in zebrafish larvae."( Delineating the protective action of cordycepin against cadmium induced oxidative stress and gut inflammation through downregulation of NF-κB pathway.
Almutairi, BO; Arockiaraj, J; Arokiyaraj, S; Murugan, R; Priya, PS; Shanjeev, P, 2023
)
1.9
"Cordycepin treatment significantly reduced the cell survival rate of T24 cells in a concentration-dependent manner, which was associated with the induction of apoptosis."( Cordycepin induces apoptosis in human bladder cancer T24 cells through ROS-dependent inhibition of the PI3K/Akt signaling pathway.
Cha, HJ; Choi, YH; Hong, SH; Hwang, EJ; Jeong, SJ; Jin, CY; Kim, GY; Kim, SO; Lee, H; Leem, SH; Park, C; Park, SH, 2019
)
2.68
"Cordycepin treatment significantly decreased inflammation, granulation tissue and fibrous tissue formation and prevented formation of esophageal strictures shown by histopathological damage score and stenosis indexes compared to control group (p < 0.01). "( Cordycepin prevents the esophageal stricture formation in the alkali-burn rat model by exerting anti-inflammatory and antifibrotic effects.
Altinel, Y; Biltekin, B; Buğdaycı, N; Çelik, A; Ercan, G; Gulcicek, OB; Hacım, NA; Karagulle, OO; Meriç, S; Solmaz, A; Tartar, RI; Yavuz, E; Yiğitbaş, H, 2021
)
3.51
"Cordycepin treatment significantly decreased DENV protein at a half-maximal effective concentration (EC50) of 26.94 μM."( Cordycepin Inhibits Virus Replication in Dengue Virus-Infected Vero Cells.
Jantakee, K; Kaewkod, T; Lee, VS; Nimmanpipug, P; Panwong, S; Panya, A; Sawasdee, N; Songprakhon, P; Tragoolpua, Y; Yenchitsomanus, PT, 2021
)
2.79
"Cordycepin treatment significantly reversed cognitive decline in diabetic mice in the NOR test and ameliorated antioxidant defenses."( The effect of cordycepin on brain oxidative stress and protein expression in streptozotocin-induced diabetic mice.
Fungfuang, W; Parunyakul, K; Phaonakrop, N; Roytakul, S; Srisuksai, K, 2021
)
1.7
"Cordycepin treatment significantly alleviated neurological deficits, brain edema, and perihematomal tissue damage following ICH."( Cordycepin confers neuroprotection in mice models of intracerebral hemorrhage via suppressing NLRP3 inflammasome activation.
Cai, Y; Cheng, Y; Shang, H; Song, Y; Wei, Y; Wu, Z; Yang, W; Zhao, W, 2017
)
2.62
"Cordycepin treatment to enhance osteogenesis may be considered a potential therapeutic approach to prevent the development of alcohol-induced ONFH."( The Protective Effect of Cordycepin On Alcohol-Induced Osteonecrosis of the Femoral Head.
Chen, YX; Gao, YS; Mei, J; Xu, ZL; Yin, JH; Yu, XW; Zhang, CQ; Zhu, DY, 2017
)
2.2
"Cordycepin treatment also reduced the activation of CREB."( Cordycepin inhibits lipopolysaccharide-induced cell migration and invasion in human colorectal carcinoma HCT-116 cells through down-regulation of prostaglandin E2 receptor EP4.
Cha, HJ; Choi, YH; Hong, SH; Jeong, JW; Kim, CH; Kim, GY; Kim, WJ; Park, C; Park, SH; Song, KS, 2018
)
2.64
"Cordycepin treatment dramatically reversed the relative abundance of two dominant bacterial phyla (Bacteroidetes and Firmicutes) in the high-fat-diet-induced obese rats, resulting in abundance similar to that of the chow diet group."( Cordycepin reduces weight through regulating gut microbiota in high-fat diet-induced obese rats.
An, Y; Chen, Z; Li, S; Li, Y; Liu, M; Luan, W; Tang, X; Wang, C; Wang, X; Wu, L; Xu, H; Yu, L, 2018
)
2.64
"Cordycepin treatment alleviated these MPTP-induced changes."( Cordycepin mitigates MPTP-induced Parkinson's disease through inhibiting TLR/NF-κB signaling pathway.
Cheng, C; Zhu, X, 2019
)
2.68
"Cordycepin treatment caused a dose-dependent increase of pro-apoptotic Bax and decrease of anti-apoptotic Bcl-2, triggering collapse of the mitochondrial membrane potential and activation of caspase-9 and -3."( Involvement of autophagy in cordycepin-induced apoptosis in human prostate carcinoma LNCaP cells.
Choi, YH; Jeong, YK; Kim, GY; Kim, SO; Kim, WJ; Lee, HH; Moon, SK; Yoo, YH, 2014
)
1.42
"Cordycepin treatment attenuated the TBI-induced impairments in a dose-dependent manner, and played a role in protecting BBB integrity."( Cordycepin attenuates traumatic brain injury-induced impairments of blood-brain barrier integrity in rats.
He, Y; Liu, Y; Si, Z; Wang, A; Wang, D; Wang, K; Xu, S; Yuan, J; Zhang, S, 2016
)
2.6
"Cordycepin treatment, at a dose of 200 microM (IC(50)) during cell-cycle progression resulted in significant and dose-dependent growth inhibition, which was largely due to G2/M-phase arrest, and resulted in an up-regulation of p21WAF1 expression, independent of the p53 pathway."( Cordycepin causes p21WAF1-mediated G2/M cell-cycle arrest by regulating c-Jun N-terminal kinase activation in human bladder cancer cells.
Choi, WS; Kim, SK; Kim, WJ; Lee, SJ; Moon, SK, 2009
)
2.52
"Cordycepin treatment resulted in G2/M-phase cell-cycle arrest, which was associated with increased p21WAF1 levels and reduced amounts of cyclin B1, Cdc2, and Cdc25c in a p53-independent pathway."( c-Jun N-terminal kinase 1 is required for cordycepin-mediated induction of G2/M cell-cycle arrest via p21WAF1 expression in human colon cancer cells.
Jung, KH; Kim, WJ; Lee, SJ; Moon, GS; Moon, SK, 2010
)
1.35
"Cordycepin-treated cells showed phosphatidylserine valgus, suggesting the existence of early apoptosis."( Cordycepin induces apoptosis by enhancing JNK and p38 kinase activity and increasing the protein expression of Bcl-2 pro-apoptotic molecules.
Fang, X; He, W; Jiang, TT; Song, Y; Ye, J; Zhang, MF, 2010
)
2.52
"Cordycepin treatment at 120 microM and 80 microM, respectively, induced apoptosis in both cells and caused the increase of cell accumulation in a time-dependent manner at the apoptotic sub-G1 phase, as evidenced by the flow cytometry (FCM) and annexin V-fluorescein isothiocyanate (FITC) analyses."( Cordycepin induces apoptosis in human neuroblastoma SK-N-BE(2)-C and melanoma SK-MEL-2 cells.
Baik, JS; Cho, YS; Jeong, YK; Kim, KS; Kwon, HY; Lee, YC, 2012
)
2.54
"Cordycepin-treated groups were administered daily doses of oral cordycepin at 5, 10, and 20 mg/kg body weight for 4 months."( Effect of long-term administration of cordycepin from Cordyceps militaris on testicular function in middle-aged rats.
Hwang, SY; Kim, IW; Kim, SK; Kim, SW; Lee, SC; Sohn, SH; Ye, MB, 2012
)
1.37
"Cordycepin treatment results in shorter poly(A) tails, and a reduction in the efficiency of mRNA cleavage and transcription termination is observed, indicating that the effects of cordycepin on 3' processing in cells are similar to those described in in vitro reactions."( Inhibition of polyadenylation reduces inflammatory gene induction.
Barthet-Barateig, A; De Moor, CH; Khurshid, A; Knox, AJ; Kondrashov, A; Meijer, HA; Pang, L; Parker, HN; Sicard, M; Tessier, S, 2012
)
1.1
"Cordycepin-treated, ADA-inhibited, TdT-positive cells undergo the classic changes associated with drug-induced apoptosis: reduction in cell volume, chromatin clumping, membrane blebbing, and 180-bp multimer DNA laddering on agarose gels."( Induction of apoptosis by cordycepin in ADA-inhibited TdT-positive leukemia cells.
Koç, Y; McCaffrey, R; Sweeney, EB; Urbano, AG, 1996
)
1.32
"Upon treatment with cordycepin, MSCs were investigated for cell viability, doubling time, key gene/protein expression, galactosidase-associated senescence assay, relative telomere length, and telomerase expression."( Cordycepin Enhances
Chaicharoenaudomrung, N; Chueaphromsri, P; Kunhorm, P; Noisa, P; Phonchai, R,
)
1.89
"Treatment with cordycepin or cisplatin (2 μg/mL) alone failed to induce cell death in T24R2 cells, but combination treatment with these drugs significantly induced apoptosis through mitochondrial pathways, including depolarization of mitochondrial membranes, decrease in anti-apoptotic proteins Bcl-2, Bcl-xL, and Mcl-1, and increase in pro-apoptotic proteins Bak and Bax."( Cordycepin Resensitizes T24R2 Cisplatin-Resistant Human Bladder Cancer Cells to Cisplatin by Inactivating Ets-1 Dependent MDR1 Transcription.
Han, HT; Hwangbo, C; Jeong, JW; Kim, KD; Kim, M; Lee, KW; Lee, Y; Madhi, H; Oh, SS; Park, S; Yoo, J, 2020
)
2.34
"Co-treatment with cordycepin and cDDP inhibited cell growth, migration, and metastasis, as well as induced apoptosis."( Cordycepin enhances the chemosensitivity of esophageal cancer cells to cisplatin by inducing the activation of AMPK and suppressing the AKT signaling pathway.
Chen, DL; Gao, Y; He, MF; Huang, S; Liao, XZ; Zhang, JX; Zheng, ZS; Zhou, M, 2020
)
2.32
"Treatment of cordycepin controlled SiHa and HeLa cervical cancer cell growth, increased the rate of their apoptosis, and interfered with cell cycle, specifically elongated S-phase. "( Cordycepin Downregulates Cdk-2 to Interfere with Cell Cycle and Increases Apoptosis by Generating ROS in Cervical Cancer Cells: in vitro and in silico Study.
Halim, MA; Khan, MA; Khorram, MS; Kiefer, R; Saif, K; Shawon, J; Tania, M, 2019
)
2.33
"Treatment with cordycepin resulted in increased apoptosis in HCT116 cells; however, flow cytometic analysis demonstrated that apoptosis was notably decreased in the Bax‑/‑ HCT116 cell lines, but not in the p53‑/‑ HCT116 cell lines."( Cordycepin induces Bax‑dependent apoptosis in colorectal cancer cells.
Du, RL; Fei, J; Li, SZ; Ren, JW; Zhang, XD, 2019
)
2.3
"Treatment of cordycepin results in the increasing expression of epithelial marker, Ecadherin while no significant effect was found on N-cadherin α-catenin and β-catenin."( Cordycepin suppresses integrin/FAK signaling and epithelial-mesenchymal transition in hepatocellular carcinoma.
Ko, BS; Liang, SM; Liou, JY; Liu, CC; Liu, TA; Lu, YJ; Shen, TL; Tzean, SS; Yao, WL, 2014
)
2.2
"Treatment with cordycepin largely reduced oleic acid (OA)-elicited intracellular lipid accumulation and increased AMPK activity in a dose-dependent manner."( Cordycepin activates AMP-activated protein kinase (AMPK) via interaction with the γ1 subunit.
Guo, P; Guo, Y; He, H; Luan, H; Su, Y; Sun, G; Sun, X; Wang, X; Wu, C; Zhang, X; Zhu, H; Zhu, P, 2014
)
2.18
"Pretreatment with cordycepin significantly inhibited the production of PGE2 and NO induced by IL-1β. "( Cordycepin prevented IL-β-induced expression of inflammatory mediators in human osteoarthritis chondrocytes.
Chen, H; Cheng, S; Peng, L; Shen, Y; Ying, X; Yu, K, 2014
)
2.18
"Treatment with cordycepin increased Wnt-related genes' expression whereas supplementation of Wnt pathway inhibitor reversed its protective effects."( Cordycepin prevents oxidative stress-induced inhibition of osteogenesis.
Jiang, C; Liu, Y; Lu, Y; Wang, F; Yin, P; Yu, X; Zhou, Z, 2015
)
2.2
"Treatment with cordycepin significantly inhibited cell growth in a concentration-dependent manner by inducing apoptosis but not necrosis."( Induction of apoptosis by cordycepin via reactive oxygen species generation in human leukemia cells.
Choi, YH; Hong, SH; Jeong, JW; Jeong, YK; Jin, CY; Kim, GY; Lee, JD; Park, C; Yoo, YH, 2011
)
1.01
"The treatment with cordycepin, when protected by an inhibitor of ADA, can prolong the survival of T."( Susceptibility of Trypanosoma evansi to cordycepin.
Costa, MM; Da Silva, AS; Duck, MR; Gressler, LT; Lopes, ST; Mazzanti, CM; Monteiro, SG; Nunes, JT; Oliveira, CB; Wolkmer, P; Zanette, RA, 2011
)
0.96

Pharmacokinetics

The levels of both adenosine and cordycepin decreased rapidly in blood around 30 min after drug administration. Four N-acyl-(propionyl-, octanoyl-, lauroyl- and stearoyl-) cordyCEpin derivatives were synthesized chemically.

ExcerptReferenceRelevance
"For slowing down the too fast metabolic velocity and increasing the bioavailability of cordycepin, four N-acyl-(propionyl-, octanoyl-, lauroyl- and stearoyl-) cordycepin derivatives were synthesized chemically and their pharmacokinetic profiles were investigated in this study."( Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
Chen, Z; Li, PM; Li, XG; Pu, SC; Wei, HP; Ye, XL; Zhong, YJ, 2009
)
0.82
" The pharmacokinetic results suggest that the levels of both adenosine and cordycepin decreased rapidly in blood around 30 min after drug administration."( Pharmacokinetics of adenosine and cordycepin, a bioactive constituent of Cordyceps sinensis in rat.
Lin, LC; Tsai, TH; Tsai, YJ, 2010
)
0.87

Compound-Compound Interactions

Cordycepin in combination with dCF produced symptoms associated with severe gastrointestinal toxicity and bone marrow toxicity. The drug combination of doxorubicin and cordyce pin effectively inhibits the growth and proliferation of LN-229 cells through multiple targets.

ExcerptReferenceRelevance
" Cordycepin in combination with dCF produced symptoms associated with severe gastrointestinal toxicity (decreased body weights, emesis, diarrhea, decreased food consumption, and necrosis of the gastrointestinal tract) and bone marrow toxicity (lymphopenia, thrombocytopenia, and depletion of hematopoietic cells)."( Toxicity of cordycepin in combination with the adenosine deaminase inhibitor 2'-deoxycoformycin in beagle dogs.
Allan, PW; Coyne, JM; Duncan, KL; Farnell, DR; Hill, DL; Page, JG; Rodman, LE; Smith, AC; Tomaszewski, JE, 1997
)
1.59
" In this study, we aimed to determine the effect of ECDI-SPs combined with a short course of cordycepin (an anti-inflammatory agent) on the long-term outcomes of mice cardiac allografts."( Ethylene carbodiimide-fixed donor splenocytes combined with cordycepin induce long-term protection to mice cardiac allografts.
Fen, N; Guanghui, L; Jiali, F; Junjie, M; Lei, Z; Lu, X; Tiantian, W; Xingqiang, L; Yuhe, G; Zheng, C; Zhongpeng, Y, 2019
)
0.98
" Cordycepin administered with doxorubicin is a potential drug combination for the treatment of glioblastoma."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.93
"To explore the complex mechanism of cordycepin combined with doxorubicin against glioblastoma using network pharmacology and biological verification."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.29
" Putative targets and the potential mechanism of action for the drug combination in glioblastoma were obtained through online databases, network construction, and enrichment analyses."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.02
" The drug combination inhibited EMT by upregulating the expression of E-cadherin protein and downregulating the expression of N-cadherin, ZEB1, and Twist1 proteins."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.02
"This study shows that the drug combination of doxorubicin and cordycepin effectively inhibits the growth and proliferation of LN-229 cells through multiple targets and multiple pathways, and the combination inhibits cell invasion and migration by regulating the EMT switch of tumor cells."( Exploring the mechanism of cordycepin combined with doxorubicin in treating glioblastoma based on network pharmacology and biological verification.
Chen, J; Liang, RS; Liu, S; Wang, CH; Zhang, Q; Zhuang, BB; Zhuang, YD, 2022
)
1.26

Bioavailability

Oral administration of cordycepin has limited practical use due to its poor bioavailability in the intestine. Four N-acyl-(propionyl-, octanoyl-, lauroyl- and stearoyl-) cordyCEpin derivatives were synthesized chemically and their pharmacokinetic profiles were investigated.

ExcerptReferenceRelevance
"For slowing down the too fast metabolic velocity and increasing the bioavailability of cordycepin, four N-acyl-(propionyl-, octanoyl-, lauroyl- and stearoyl-) cordycepin derivatives were synthesized chemically and their pharmacokinetic profiles were investigated in this study."( Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
Chen, Z; Li, PM; Li, XG; Pu, SC; Wei, HP; Ye, XL; Zhong, YJ, 2009
)
0.82
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" However, oral administration of cordycepin has limited practical use due to its poor bioavailability in the intestine."( Improvement of the multi-performance biocharacteristics of cordycepin using BiloNiosome-core/chitosan-shell hybrid nanocarriers.
Bunwatcharaphansakun, P; Iempridee, T; Jantimaporn, A; Kaewmalun, S; Kengkittipat, W; Khongkow, M; Namdee, K; Phoolcharoen, W; Yata, T; Yostawonkul, J, 2021
)
1.15
" Unfortunately, this highly effective natural antibiotic is proved to undergo rapid deamination by adenosine deaminase (ADA) in vivo and, as a consequence, its half-life is shortened and bioavailability is decreased."( Cordycepin: A review of strategies to improve the bioavailability and efficacy.
Chen, L; Chen, M; Han, C; Jiang, W; Luo, J; Miao, L, 2023
)
2.35

Dosage Studied

Cordycepin (CD) inhibited furin expression in a dosage dependent manner. In cell viability assay, cell surviving rate significantly decreased as the dosage and duration of cordyce pin treatment increased.

ExcerptRelevanceReference
" Stimulation by stripped serum or oestradiol resulted in parallel increases of proliferation and pS2 release in both time course and dose-response experiments."( Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.
Casavola, V; Correale, M; Mangia, A; Paradiso, A; Reshkin, SJ; Tedone, T,
)
0.13
"There is extensive literature on in vivo studies with cordycepin, but these studies were generally conducted without validation of the various formulations, especially in terms of the solubility of cordycepin in the dosing vehicles used."( Development of Cordycepin Formulations for Preclinical and Clinical Studies.
Adrower, C; de Moor, CH; Fischer, PM; Gershkovich, P; Lee, JB; Qin, C, 2017
)
1.06
" Despite the fact that numerous studies showed efficacy following oral dosing of cordycepin, we found that intact cordycepin was not absorbed following oral administration to rats."( A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin.
Adrower, C; Barrett, DA; Cipolla, E; de Moor, CH; Feng, W; Fischer, PM; Gandhi, RD; Gershkovich, P; Kagan, L; Kim, TH; Lee, JB; Ortori, CA; Qin, C; Radhi, M; Sarmad, S; Zgair, A, 2019
)
0.95
" Moreover, Cordycepin (CD) inhibited furin expression in a dosage dependent manner."( COVID-19 disease and malignant cancers: The impact for the
Chen, H; Chen, X; Cheng, J; Fu, J; Fu, S; He, J; Li, D; Liu, S; Liu, X; Zhang, L, 2021
)
1.01
" Cordycepin at dosage of 20 mg/kg also increased the TH level in SN."( Cordycepin improved the cognitive function through regulating adenosine A
Han, YY; Huang, SY; Li, CH; Liu, L; Mai, ZF; Shang, YJ; Su, ZY; Zeng, ZW, 2023
)
3.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
nucleoside antibioticnull
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
3'-deoxyribonucleoside
adenosinesAny purine ribonucleoside that is a derivative of adenosine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
aspartate superpathway25122
NAD de novo biosynthesis I (from aspartate)734

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency7.75360.000811.382244.6684AID686978; AID686979
PINK1Homo sapiens (human)Potency44.66842.818418.895944.6684AID624263
ParkinHomo sapiens (human)Potency44.66840.819914.830644.6684AID624263
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency4.46680.15855.287912.5893AID540303
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TPA: protein transporter TIM23Saccharomyces cerevisiae S288CIC50 (µMol)14.00000.880010.503632.9000AID493002
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki9.81330.00011.20929.9700AID31718; AID32352; AID32353
Sterol 14-alpha demethylaseTrypanosoma cruzi strain CL BrenerIC50 (µMol)100.00000.00101.707010.0000AID1207588
RNA-directed RNA polymerase IC50 (µMol)22.00000.01902.52798.8000AID86858
Carnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)IC50 (µMol)100.00000.12594.244010.0000AID1207588
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
heat shock protein 90Candida albicansEC50 (µMol)150.00000.12006.485533.8530AID2423
Histamine H1 receptorCavia porcellus (domestic guinea pig)EC50 (µMol)46.00000.00260.53341.2020AID86857
RNA-directed RNA polymerase EC50 (µMol)46.00000.00180.23482.8000AID86857
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Processvia Protein(s)Taxonomy
fatty acid metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
fatty acid beta-oxidationCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine shuttleCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
carnitine metabolic processCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
response to blue lightCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
long-chain fatty acid transportCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
carnitine O-palmitoyltransferase activityCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
protein bindingCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrial outer membraneCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
mitochondrionCarnitine O-palmitoyltransferase 1, muscle isoformHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID416870Cmax in C57BL/6 mouse at 0.5 umol/kg, po assessed as transformed cordycepin levels2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID1255098Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated PGE2 production at 1 to 10 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot analysis2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID416868Half life in C57BL/6 mouse at 0.5 umol/kg, po2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID1584731Therapeutic index, ratio EC50 for human MRC5 SV2 cells to EC50 for Trypanosoma cruzi Tulahuen CL2 intracellular amastigotes2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID1065704Drug metabolism assessed as recombinant human ADA-mediated 3'-deoxyinosine metabolite formation at 100 uM measured every 15 mins for 10 hrs by spectrophotometric analysis in presence of deoxycoformycin2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1065710Displacement of [2,8-3H]-adenosine from Trypanosoma brucei AT1/P2 expressed in bloodstream stage of Trypanosoma brucei brucei B482013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID225768Antiviral activity against polio virus type 1 in HeLa cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID229234Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines,1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID1065705Drug metabolism assessed as recombinant human ADA-mediated 3'-deoxyinosine metabolite formation at 100 uM measured every 15 mins for 10 hrs by spectrophotometric analysis2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID416743Cmax in C57BL/6 mouse at 0.5 umol/kg, po2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID1065713Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei AnTat1.1E infected in C57BL6J (B6) mouse assessed as reduction of parasitemia at 2 mg/kg, ip qd administered for 3 days measured after 40 days in presence of deoxycoformycin2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID81438Dose required to inhibit cytopathic effect of human immunodeficiency virus replication in MT-4 cells.1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID1065714Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei AnTat1.1E after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID229236Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1584732Antiparasitic activity against Trypanosoma cruzi Tulahuen CL2 intracellular amastigotes expressing beta-galactosidase infected in human MRC5 SV2 cells after 7 days by chlorophenol red beta-D-galactopyranoside-based spectrophotometric analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID31719Affinity for adenosine A1 receptor was determined, in the presence of GTP in rat brain cortex1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.
AID1065698Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1065715Trypanocidal activity against Trypanosoma brucei2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1167619Cytotoxicity against human ORL8 cells after 72 hrs by WST-1 assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID86857Inhibition HCV RNA replication2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID333675Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 after 24 hrs by [3H]hypoxanthine uptake2004Journal of natural products, Nov, Volume: 67, Issue:11
10-membered macrolides from the insect pathogenic fungus Cordyceps militaris BCC 2816.
AID416744AUC in C57BL/6 mouse at 0.5 umol/kg, po2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID228408Antiviral activity against reovirus type 1 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID81069Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells.1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID226341Antiviral activity against sindbis virus in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID751324Inhibition of NFkappaB p65 nuclear translocation in mouse RAW264.7 cells after 24 hrs by DAPI staining-based laser confocal immunofluorescent microscopic analysis2013Bioorganic & medicinal chemistry, Jan-15, Volume: 21, Issue:2
Synthesis and anti-inflammatory evaluations of β-lapachone derivatives.
AID229716GTP shift ratio of the apparent Ki values in the presence and absence of GTP.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.
AID1065694Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei AnTat1.1E after 72 hrs by WST-1 assay in presence of adenosine kinase inhibitor ABT7022013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID229026Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1065706Cytotoxicity against mouse L929 cells assessed as cell viability after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1065696Trypanocidal activity against bloodstream stage of Trypanosoma brucei after 72 hrs by WST-1 assay2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1255101Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated PGE2 production at 0.5 to 5 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot analysis 2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID220033Antiviral activity against coxsackie B4 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1255096Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated TNF-alpha production at 0.5 to 5 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot anal2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID235875Ratio of CD50 to ED50 rvaluated for inhibition of HIV replication in MT-4 cells1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis and anti-HIV activity of different sugar-modified pyrimidine and purine nucleosides.
AID1167620Selectivity index, ratio of CC50 for human ORL8 cells to EC50 for Hepatitis C virus infected in African green monkey OR6 cells2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID416871AUC in C57BL/6 mouse at 0.5 umol/kg, po assessed as transformed cordycepin levels2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID228985Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1065699Drug metabolism in human MOLT4 cells assessed as ADA-mediated inosine metabolite formation2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID416872Half life in C57BL/6 mouse at 0.5 umol/kg, po assessed as transformed cordycepin levels2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID416869Tmax in C57BL/6 mouse at 0.5 umol/kg, po assessed as transformed cordycepin levels2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID1255092Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated TNF-alpha production at 1 to 10 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot analy2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID32353Affinity for the Adenosine A1 receptor in the presence of GTP (A1+GTP) by using [3H]-DPCPX as radioligand1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID179545GTP shift was determined in rat1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID216185Anti-Herpes simplex virus type-1 activity in vero cells using plaque inhibition assay1999Journal of medicinal chemistry, Aug-26, Volume: 42, Issue:17
Virtual combinatorial syntheses and computational screening of new potential anti-herpes compounds.
AID1255097Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated TNF-alpha production at 0.5 to 5 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot anal2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID1065695Trypanocidal activity against bloodstream stage of Trypanosoma brucei after 72 hrs by WST-1 assay in presence of deoxycoformycin2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID1255102Inhibition of TLR4-mediated NF-kappaB signaling pathway in BALB/c mouse RAW264.7 cells assessed as suppression of LPS-stimulated PGE2 production at 0.5 to 5 ug/ml preincubated for 1 hr followed by LPS challenge measured after 6 hrs by immunoblot analysis 2015Journal of natural products, Oct-23, Volume: 78, Issue:10
N(6)-(2-Hydroxyethyl)adenosine in the Medicinal Mushroom Cordyceps cicadae Attenuates Lipopolysaccharide-Stimulated Pro-inflammatory Responses by Suppressing TLR4-Mediated NF-κB Signaling Pathways.
AID220034Antiviral activity against coxsackie B4 virus in HeLa cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID416742Tmax in C57BL/6 mouse at 0.5 umol/kg, po2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Synthesis and pharmacokinetic evaluation of novel N-acyl-cordycepin derivatives with a normal alkyl chain.
AID1167618Antiviral activity against Hepatitis C virus infected in African green monkey OR6 cells after 72 hrs by luciferase reporter gene assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID84402Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1065708Trypanocidal activity against bloodstream stage of Trypanosoma brucei brucei AnTat1.1E infected in C57BL6J (B6) mouse assessed as reduction of parasitemia at 2 mg/kg, ip qd measured after 30 days2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID85279Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID32352Affinity for the Adenosine A1 receptor in the absence of GTP (A1-GTP) by using [3H]DPCPX as radioligand1995Journal of medicinal chemistry, Sep-29, Volume: 38, Issue:20
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
AID224916Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1584733Cytotoxicity against human MRC5 SV2 cells assessed as reduction in cell viability after 3 days resazurin-based fluorimetric assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi.
AID86858Inhibition HCV NS5B-mediated RNA synthesis2004Journal of medicinal chemistry, Apr-22, Volume: 47, Issue:9
Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.
AID1065697Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by WST-1 assay in presence of deoxycoformycin2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
AID662565Growth inhibition of Trichomonas vaginalis T1 at 100 uM after 24 hrs by hemocytometry2012Bioorganic & medicinal chemistry letters, Jun-15, Volume: 22, Issue:12
S-Adenosylhomocysteine hydrolase of the protozoan parasite Trichomonas vaginalis: potent inhibitory activity of 9-(2-deoxy-2-fluoro-β,D-arabinofuranosyl)adenine.
AID31718Affinity for adenosine A1 receptor was determined, in the absence of GTP in rat cortical membrane.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.
AID81802Antiviral activity against (HIV-1) in MT-4 cells Value in parentheses is inhibitory concentration for cell growth (MT-4)1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159558TcCYP51 enzymatic inhibition2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159561NIH-3T3 cytotoxicity2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159562Trypanosoma brucei growth inhibition luminescent assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159557Trypanosoma brucei. Primary growth inhibition assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159559Trypanosoma cruzi. Primary growth inhibition assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159563HepG2 cytotoxicity assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159564Intra-macrophage L. donovani assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159565Trypanosoma cruzi intracellular imaging assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1159560Leishmania donovani. Primary growth inhibition assay2015Scientific reports, Mar-05, Volume: 5New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (579)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (3.63)18.7374
1990's65 (11.23)18.2507
2000's89 (15.37)29.6817
2010's276 (47.67)24.3611
2020's128 (22.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.62 (24.57)
Research Supply Index6.39 (2.92)
Research Growth Index5.24 (4.65)
Search Engine Demand Index91.37 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (32.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.17%)5.53%
Reviews22 (3.72%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other569 (96.11%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I/II Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia [NCT00709215]Phase 1/Phase 244 participants (Anticipated)Interventional2008-06-30Recruiting
A Phase I Study of Cordycepin (NSC 63984) Plus 2'-Deoxycoformycin (NSC 218321) in Patients With Refractory TdT-Positive Leukemia [NCT00003005]Phase 114 participants (Actual)Interventional1997-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]